UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Targeted therapies in rheumatoid arthritis
Boumans, M.J.H.
Publication date
2012
Link to publication
Citation for published version (APA):
Boumans, M. J. H. (2012). Targeted therapies in rheumatoid arthritis.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Table 1: Baseline characteristics of the study patients
IgM-RF = IgM rheumatoid factor; SD = standard deviation; ACPA = anti-citrullinated peptide antibodies; DAS28 = Disease Activity Score 28-joint assessment; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; SHS = Sharp-van der Heijde scoring method; DMARDs = Disease Modifying Anti-Rheumatic Drugs
Demographics (n=9)
Female, no. (%) 7 (78)
Age, median (range) years 53(24-45)
Baseline disease status
IgM-RF positive, no. (%) 4 (44)
ACPA positive, no. (%) 8 (89)
DAS28, mean (± SD) 4.10 (±0.52 )
ESR, median (range) mm/hour 10 (2-23)
CRP, median (range) mg/l 12 (1-25)
Disease duration, median (range) years 16 (5-24)
Nodular disease, no. (%) 2 (22)
Erosive disease, no. (%) 9 (100)
Total SHS, median (range) 40 (10-87)
Medication
Concomitant methotrexate, no. (%) 9 (100)
Concomitant methotrexate dosage, median (range) 10 (5-25)
Concomitant oral prednisone, no. (%) 5 (56)
Concomitant oral prednisone dosage, median (range) 2.5 (0-10)
No. of previous DMARDs, median (range) 3 (2-6)
